From chloroquine to artemisinin-based combination therapy: the Sudanese experience
- PMID: 16879742
- PMCID: PMC1590042
- DOI: 10.1186/1475-2875-5-65
From chloroquine to artemisinin-based combination therapy: the Sudanese experience
Abstract
Background: In Sudan, chloroquine (CQ) remains the most frequently used drug for falciparum malaria for more than 40 years. The change to artemisinin-based combination therapy (ACT) was initiated in 2004 using the co-blister of artesunate + sulfadoxine/pyrimethamine (AS+SP) and artemether + lumefantrine (ART+LUM), as first- and second-line, respectively. This article describes the evidence-base, the process for policy change and it reflects the experience of one year implementation. Relevant published and unpublished documents were reviewed. Data and information obtained were compiled into a structured format.
Case description: Sudan has used evidence to update its malaria treatment to ACTs. The country moved without interim period and proceeded with country-wide implementation instead of a phased introduction of the new policy. The involvement of care providers and key stakeholders in a form of a technical advisory committee is considered the key issue in the process. Development and distribution of guidelines, training of care providers, communication to the public and provision of drugs were given great consideration. To ensure presence of high quality drugs, a system for post-marketing drugs surveillance was established. Currently, ACTs are chargeable and chiefly available in urban areas. With the input from the Global Fund to fight AIDs, Tuberculosis and Malaria, AS+SP is now available free of charge in 10 states.
Conclusion: Implementation of the new policy is affected by the limited availability of the drugs, their high cost and limited pre-qualified manufacturers. Substantial funding needs to be mobilized by all partners to increase patients' access for this life-saving intervention.
Figures
Similar articles
-
A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan.Malar J. 2007 Jul 15;6:92. doi: 10.1186/1475-2875-6-92. Malar J. 2007. PMID: 17631681 Free PMC article. Clinical Trial.
-
Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic.Clin Infect Dis. 2004 Oct 15;39(8):1139-47. doi: 10.1086/424512. Epub 2004 Sep 27. Clin Infect Dis. 2004. PMID: 15486837 Clinical Trial.
-
[Combined antimalarial therapy using artemisinin].Parassitologia. 2004 Jun;46(1-2):85-7. Parassitologia. 2004. PMID: 15305693 Review. Italian.
-
Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa.Malar J. 2007 Dec 21;6:170. doi: 10.1186/1475-2875-6-170. Malar J. 2007. PMID: 18154655 Free PMC article. Clinical Trial.
-
Coartemether (artemether and lumefantrine): an oral antimalarial drug.Expert Rev Anti Infect Ther. 2004 Apr;2(2):181-96. doi: 10.1586/14787210.2.2.181. Expert Rev Anti Infect Ther. 2004. PMID: 15482185 Review.
Cited by
-
Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan.Malar J. 2012 Dec 5;11:404. doi: 10.1186/1475-2875-11-404. Malar J. 2012. PMID: 23217037 Free PMC article.
-
Descriptive study on the efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Sudan.Eur J Clin Pharmacol. 2010 Mar;66(3):231-7. doi: 10.1007/s00228-009-0750-4. Eur J Clin Pharmacol. 2010. PMID: 20187287 Clinical Trial.
-
A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan.Malar J. 2007 Jul 15;6:92. doi: 10.1186/1475-2875-6-92. Malar J. 2007. PMID: 17631681 Free PMC article. Clinical Trial.
-
Policy dialogue to improve health outcomes in low income countries: what are the issues and way forward?BMC Health Serv Res. 2016 Jul 18;16 Suppl 4(Suppl 4):217. doi: 10.1186/s12913-016-1450-2. BMC Health Serv Res. 2016. PMID: 27454794 Free PMC article.
-
Selection of pfdhfr/pfdhps alleles and declining artesunate/sulphadoxine-pyrimethamine efficacy against Plasmodium falciparum eight years after deployment in eastern Sudan.Malar J. 2013 Jul 19;12:255. doi: 10.1186/1475-2875-12-255. Malar J. 2013. PMID: 23870667 Free PMC article.
References
-
- Malik EM, Saeed OK. Malaria in Sudan: past, present and the future. Gazera Journal of Health Sciences. 2004;1:47–53.
-
- Himeidan Yel-S, Dukeen MY, El-Rayah el-A, Adam I. Anopheles arabiensis: abundance and insecticide resistance in an irrigated area of eastern Sudan. East Mediterr Health J. 2004;10:167–174. - PubMed
-
- Abdel-Hameed AA. Antimalarial drug resistance in the Eastern Mediterranean Region. East Mediterr Health J. 2003;9:492–508. - PubMed
-
- Yousif MA, Adeel AA. Antimalarials prescribing pattern in Gazera State: precepts and practices. East Mediterr Healh J. 2000;6:939–947. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous